{"id":"https://openalex.org/W2340312426","doi":"https://doi.org/10.1016/j.clinthera.2016.03.031","title":"Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes","display_name":"Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes","alternate_titles":[],"publication_year":2016,"publication_date":"2016-04-13","ids":{"openalex":"https://openalex.org/W2340312426","doi":"https://doi.org/10.1016/j.clinthera.2016.03.031","mag":"2340312426","pmid":"https://pubmed.ncbi.nlm.nih.gov/27085585"},"language":"en","primary_location":{"id":"doi:10.1016/j.clinthera.2016.03.031","doi":"https://doi.org/10.1016/j.clinthera.2016.03.031","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.clinthera.2016.03.031","pdf_url":null,"source":{"id":"https://openalex.org/S185879095","display_name":"Clinical Therapeutics","issn_l":"0149-2918","issn":["0149-2918","1879-114X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2340312426"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.clinthera.2016.03.031","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034574461","display_name":"Sven K\u00f6hler","orcid":"https://orcid.org/0000-0002-6032-7588","observed_orcids":["https://orcid.org/0000-0002-6032-7588"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Sven Kohler","raw_affiliation_strings":["Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany. Electronic address: sven.kohler@boehringer-ingelheim.com","Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany. Electronic address: sven.kohler@boehringer-ingelheim.com","institution_ids":["https://openalex.org/I1330995197"]},{"raw_affiliation_string":"Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073988431","display_name":"Afshin Salsali","orcid":"https://orcid.org/0000-0003-2763-0486","observed_orcids":["https://orcid.org/0000-0003-2763-0486"]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Afshin Salsali","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007480850","display_name":"Stefan Hantel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Stefan Hantel","raw_affiliation_strings":["Boehringer Ingelheim Pharma GmbH, Biberach an der Riss, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharma GmbH, Biberach an der Riss, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060236174","display_name":"Stefan Kaspers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Stefan Kaspers","raw_affiliation_strings":["Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056064349","display_name":"Hans Juergen Woerle","orcid":"https://orcid.org/0000-0003-2595-1411","observed_orcids":["https://orcid.org/0000-0003-2595-1411"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hans J. Woerle","raw_affiliation_strings":["Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085739516","display_name":"Gabriel Kim","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gabriel Kim","raw_affiliation_strings":["Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5012223927","display_name":"Uli C. Broedl","orcid":"https://orcid.org/0000-0001-9893-7747","observed_orcids":["https://orcid.org/0000-0001-9893-7747"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Uli C. Broedl","raw_affiliation_strings":["Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany","institution_ids":["https://openalex.org/I1330995197"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5034574461"],"corresponding_institution_ids":["https://openalex.org/I1330995197"],"apc_list":{"value":4240,"currency":"USD","value_usd":4240},"apc_paid":{"value":4240,"currency":"USD","value_usd":4240},"fwci":1.9345,"has_fulltext":false,"cited_by_count":93,"citation_normalized_percentile":{"value":0.87818575,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":94,"max":100},"biblio":{"volume":"38","issue":"6","first_page":"1299","last_page":"1313"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9739999771118164},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.9509999752044678},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.9079999923706055},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.9739999771118164},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.9269999861717224},{"id":"https://openalex.org/keywords/urinary-tract-infection","display_name":"urinary tract infection","score":0.9129999876022339},{"id":"https://openalex.org/keywords/genital-tract-infection","display_name":"genital tract infection","score":0.9150000214576721},{"id":"https://openalex.org/keywords/hypovolemia","display_name":"hypovolemia","score":0.9459999799728394},{"id":"https://openalex.org/keywords/drug-induced-nephropathy","display_name":"drug-induced nephropathy","score":0.31200000643730164},{"id":"https://openalex.org/keywords/drug-induced-nephritis","display_name":"drug-induced nephritis","score":0.4309999942779541},{"id":"https://openalex.org/keywords/drug-induced-nephrotoxicity","display_name":"drug-induced nephrotoxicity","score":0.6169999837875366},{"id":"https://openalex.org/keywords/drug-induced-liver-injury","display_name":"drug-induced liver injury","score":0.6129999756813049},{"id":"https://openalex.org/keywords/drug-induced-dermatitis","display_name":"drug-induced dermatitis","score":0.4880000054836273}],"concepts":[{"id":"https://openalex.org/C2775887513","wikidata":"https://www.wikidata.org/wiki/Q5373824","display_name":"Empagliflozin","level":4,"score":0.9935133457183838},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9113116264343262},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7611526250839233},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7392698526382446},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.6611868143081665},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5610489845275879},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5144103169441223},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.49380382895469666},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.4648996889591217},{"id":"https://openalex.org/C2777422806","wikidata":"https://www.wikidata.org/wiki/Q409898","display_name":"Dapagliflozin","level":4,"score":0.42084527015686035},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.15170010924339294},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007003","descriptor_name":"Hypoglycemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D007003","descriptor_name":"Hypoglycemia","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D014552","descriptor_name":"Urinary Tract Infections","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D014552","descriptor_name":"Urinary Tract Infections","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D015994","descriptor_name":"Incidence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.clinthera.2016.03.031","doi":"https://doi.org/10.1016/j.clinthera.2016.03.031","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.clinthera.2016.03.031","pdf_url":null,"source":{"id":"https://openalex.org/S185879095","display_name":"Clinical Therapeutics","issn_l":"0149-2918","issn":["0149-2918","1879-114X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Therapeutics","raw_type":"journal-article"},{"id":"pmid:27085585","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27085585","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical therapeutics","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1016/j.clinthera.2016.03.031","doi":"https://doi.org/10.1016/j.clinthera.2016.03.031","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.clinthera.2016.03.031","pdf_url":null,"source":{"id":"https://openalex.org/S185879095","display_name":"Clinical Therapeutics","issn_l":"0149-2918","issn":["0149-2918","1879-114X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":43,"referenced_works":["https://openalex.org/W1504657738","https://openalex.org/W1682854201","https://openalex.org/W1714643869","https://openalex.org/W1770274352","https://openalex.org/W1834962231","https://openalex.org/W1847388060","https://openalex.org/W1899868128","https://openalex.org/W1974583668","https://openalex.org/W1990025047","https://openalex.org/W1995006519","https://openalex.org/W2008687581","https://openalex.org/W2023384663","https://openalex.org/W2048875545","https://openalex.org/W2051243940","https://openalex.org/W2052503411","https://openalex.org/W2066620859","https://openalex.org/W2067448646","https://openalex.org/W2072040765","https://openalex.org/W2090979363","https://openalex.org/W2097620901","https://openalex.org/W2101344933","https://openalex.org/W2101374656","https://openalex.org/W2104183157","https://openalex.org/W2109093140","https://openalex.org/W2119981294","https://openalex.org/W2128219379","https://openalex.org/W2134855422","https://openalex.org/W2137069992","https://openalex.org/W2137107263","https://openalex.org/W2138173919","https://openalex.org/W2142065502","https://openalex.org/W2146264128","https://openalex.org/W2152413054","https://openalex.org/W2153336680","https://openalex.org/W2157405334","https://openalex.org/W2165956693","https://openalex.org/W2169669025","https://openalex.org/W2171049608","https://openalex.org/W2171471305","https://openalex.org/W2202866687","https://openalex.org/W2338390141","https://openalex.org/W6703912032","https://openalex.org/W7074179912"],"related_works":["https://openalex.org/W2653321410","https://openalex.org/W3021964749","https://openalex.org/W2885416375","https://openalex.org/W2807842235","https://openalex.org/W4398171858","https://openalex.org/W2898471340","https://openalex.org/W2342056230","https://openalex.org/W2556749067","https://openalex.org/W2508200983","https://openalex.org/W6920709042"],"abstract_inverted_index":{"PURPOSE:":[0],"The":[1,128,174,217,273,323],"aim":[2],"of":[3,14,86,130,162,176,194,219,275,325],"this":[4,350],"analysis":[5,352],"was":[6,110,143,155,183,225,281,299,354],"to":[7,25,98,135,360],"establish":[8],"the":[9,87,117,197,254,345],"safety":[10],"profile":[11],"and":[12,66,113,122,140,192,202,233,239,251,259,288,294,298,319,337,342,365],"tolerability":[13],"empagliflozin":[15,47,54,119,123,150,199,203,231,237,256,260,285,289,302,308,362,366],"in":[16,60,80,102,116,146,167,196,227,253,311,372],"patients":[17,38,81,147,168,195,228,312,373],"with":[18,39,42,149,152,158,179,222,230,278,283,301,374],"type":[19],"2":[20],"diabetes":[21],"mellitus":[22],"(T2DM)":[23],"according":[24],"pooled":[26],"data":[27,34],"from":[28,37],"several":[29],"clinical":[30,68],"trials.":[31,106],"METHODS:":[32],"Pooled":[33],"were":[35,77,96,340,369],"analyzed":[36],"T2DM":[40],"treated":[41,148,229],"placebo":[43,244,306],"(n":[44,50,57],"=":[45,51,58],"3695),":[46],"10":[48,120,200,238,257,286,309,363],"mg":[49,56,125,205,262,291,304,310,368],"3806),":[52],"or":[53,214,270,307],"25":[55,124,204,240,261,290,303,367],"4782)":[59],"17":[61],"randomized,":[62],"Phase":[63],"I,":[64],"II,":[65],"III":[67],"trials":[69],"plus":[70],"6":[71],"extension":[72],"studies.":[73],"Adverse":[74],"events":[75,177,220],"(AEs)":[76],"assessed":[78],"descriptively":[79],"who":[82],"took":[83],"\u22651":[84],"dose":[85],"study":[88],"drug.":[89],"AE":[90],"incidence":[91,129,175,218,274],"rates":[92],"per":[93],"100":[94],"patient-years":[95,115,235],"calculated":[97],"adjust":[99],"for":[100,236],"differences":[101],"drug":[103],"exposure":[104,109,359],"across":[105,185,344],"FINDINGS:":[107],"Total":[108],"3254,":[111],"3840,":[112],"5649":[114],"placebo,":[118,165,198,255,284],"mg,":[121,201,241,258,287,364],"groups,":[126,206,263],"respectively.":[127],"any":[131],"AEs,":[132,139],"AEs":[133,142,276],"leading":[134],"treatment":[136,186,346],"discontinuation,":[137],"severe":[138],"serious":[141],"no":[144],"higher":[145,226,300],"than":[151,243,305],"placebo.":[153],"Empagliflozin":[154],"not":[156],"associated":[157],"an":[159],"increased":[160],"risk":[161],"hypoglycemia":[163],"versus":[164],"except":[166],"on":[169,356],"background":[170],"sulfonylurea":[171],"and/or":[172],"insulin.":[173],"consistent":[178,221,277],"urinary":[180,209],"tract":[181,210],"infection":[182,224],"similar":[184,282,343],"groups":[187],"(9.4-11.3/100":[188],"patient-years);":[189],"0.4%,":[190],"0.2%,":[191],"0.3%":[193],"respectively,":[207,264],"had":[208,265],"infections":[211,267],"that":[212,268,353],"required":[213,269],"prolonged":[215,271],"hospitalization.":[216,272],"genital":[223,266],"(4.7":[232],"5.0/100":[234],"respectively)":[242,297],"(1.3/100":[245],"patient-years),":[246],"but":[247],"only":[248],"0.1%,":[249,250],"<0.1%":[252],"volume":[279],"depletion":[280],"(1.6,":[292],"1.5,":[293],"1.3/100":[295],"patient-years,":[296,321],"aged":[313],">75":[314],"years":[315],"(4.4":[316],"vs":[317],"2.3":[318],"2.5/100":[320],"respectively).":[322],"incidences":[324],"bone":[326],"fractures,":[327],"malignancies,":[328],"decreased":[329],"renal":[330],"function,":[331],"hepatic":[332],"injury,":[333],"venous":[334],"thromboembolic":[335],"events,":[336],"diabetic":[338],"ketoacidosis":[339],"low":[341],"groups.":[347],"IMPLICATIONS:":[348],"In":[349],"predefined":[351],"based":[355],">9000":[357],"patient-years'":[358],"empagliflozin,":[361],"well":[370],"tolerated":[371],"T2DM.":[375]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2340312426","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":8},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":9},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":12},{"year":2017,"cited_by_count":22},{"year":2016,"cited_by_count":10}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
